HCV-related liver transplantation and post-transplant survival rates in Europe have improved rapidly

April 13, 2018, European Association for the Study of the Liver

HCV-related liver transplantation rates in Europe have declined dramatically since the availability of direct-acting antiviral (DAA) drugs and survival rates after transplantation have reached an all-time high. A study presented today at The International Liver Congress 2018 in Paris, France, has found that the percentage of liver transplants performed as a result of hepatitis C virus (HCV) infection has more than halved since the availability of DAA drugs, and that post-transplant survival rates among those with HCV infection are now similar to those reported in patients with hepatitis B virus (HBV) infection.

"Direct-acting antiviral drugs have revolutionized the treatment of HCV-infected individuals—even those with advanced liver disease," explained Dr. Giovanni Perricone from the ASST Great Metropolitan Hospital Niguarda in Milan, Italy, who presented the study findings today. "Unlike the older HCV treatment regimens involving ribavirin and pegylated interferon, these newer agents are highly effective and well tolerated across genotypes, and we have shown previously that the remarkable clinical improvements that can be achieved using these agents can lead to the delisting of some individuals waiting for liver transplantation."

In the latest research conducted by Dr. Perricone and colleagues, data from the European Liver Transplant Registry from between January 2007 and June 2017 were reviewed, involving a total of 36,382 adults who underwent liver transplantation as a result of HCV, HBV, or non-alcoholic steatohepatitis (NASH). To assess the impact of DAAs on liver transplantation rates, data were analyzed in separate treatment eras: the interferon (IFN) era from 2007 to 2010, the protease inhibitor (PI) era from 2011 to 2013, and the second-generation DAA era from 2014 to June 2017.

The percentage of conducted as a result of HCV decreased from 22.8% during the IFN era to 10.6% during the DAA era. In contrast, the percentage of transplants conducted as a result of NASH increased from 1.1% to 6.2%. Within the DAA era, the percentage of liver transplants due to HCV decreased from 21.1% during the first half of 2014 to 10.6% during the first half of 2017.

According to Dr. Perricone, the decreased requirement for liver transplantation during the DAA era was more pronounced in patients with HCV related to decompensated (-68.8%) than in those with HCV-related hepatocellular carcinoma (-34.0%). The 3-year survival of liver recipients with HCV infection has also improved from 65.1% in the IFN era to 76.9% in the DAA era—a survival rate that is now comparable to that of patients with HBV infection (78.0%) (p=0.38).

"Our study provides clear evidence that DAAs are changing the epidemiology of , at least in countries like Italy where the prevalence of HCV infection is high," said Dr. Perricone. "We anticipate that rates of HCV-related transplantation will continue to decline as more patients gain access to these highly effective treatments."

"For the first time in many years, we have also seen improved survival in transplant recipients with HCV infection, and this can be attributed directly to the availability of DAA drugs."

"These are very important data that emphasize the effectiveness of DAA therapies against HCV," said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. "These data are important, especially as a recent Cochrane report has concluded that there is not sufficient evidence to understand how sustained virological response affects long-term clinical outcomes."

Explore further: Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

Related Stories

Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

April 11, 2018
Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis ...

Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

January 10, 2017
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II ...

Treatment of HCV allows for sustained removal from the liver transplant waiting list

April 21, 2017
A new European study presented today demonstrated that patients with chronic Hepatitis C virus (HCV) and severe liver damage, taken off the liver transplant list as a result of successful direct-acting antiviral (DAA) therapy, ...

Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients

April 25, 2015
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation ...

20-year survival expected for 4 out of 5 children who receive liver transplants

April 14, 2016
A new study presented today shows that 20-year survival after childhood liver transplantation can be expected for almost 80% of patients. The study, presented at The International Liver CongressTM 2016 in Barcelona, Spain, ...

New data reveals positive outcomes for hepatitis C transplant patients

April 11, 2014
New research announced at the International Liver Congress 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

Recommended for you

Yeast species used in food industry causes disease in humans

July 19, 2018
A major cause of drug-resistant clinical yeast infections is the same species previously regarded as non-pathogenic and commonly used in the biotechnology and food industries. The study, published on July 19th in the open-access ...

Deadly Rift Valley fever: New insight, and hope for the future

July 19, 2018
Health control measures alone could be ineffective in the long term fight against the deadly Rift Valley fever which affects both humans and animals, a new study in the journal PNAS reports.

New guidelines to diagnose, manage rare endocrine disorders

July 19, 2018
International guidelines have been published for the first time to help doctors around the globe diagnose and manage patients with a very rare set of endocrine diseases known as pseudohypoparathyroidism and its related disorders, ...

Overuse of antibiotics not what the doctor ordered

July 19, 2018
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community ...

Alcohol-related cirrhosis deaths skyrocket in young adults

July 18, 2018
Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.

Hidden blood in feces may signal deadly conditions

July 17, 2018
(HealthDay)—Even if it's not visible to the naked eye, blood in the stool can be serious—a sign of a potentially fatal disease other than colon cancer, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.